Which medication is considered a first-line treatment for relapsing forms of MS?

Interferon beta is regarded as a first-line treatment for relapsing forms of multiple sclerosis (MS) due to its ability to modulate the immune system and reduce the frequency and severity of relapses. This medication helps to decrease inflammation and minimize the activity of the disease, which is particularly important in relapsing MS, where patients experience recurrent attacks of neurological symptoms.

Corticosteroids, while they are commonly used to manage acute exacerbations or relapses of MS, are not considered a long-term treatment for disease management. Instead, they serve more as a temporary measure to reduce inflammation during relapses.

Antidepressants are used to address the symptoms of depression that can occur in MS patients, but they do not have a direct impact on the underlying disease process or the frequency of relapses.

Monoclonal antibodies, while effective for certain types of MS and may be used as second-line treatments, are not first-line options due to their potential for more severe side effects and more complex administration, typically requiring infusion or injection in a clinical setting.

Thus, considering the mechanisms of action, clinical guidelines, and treatment goals, interferon beta is clearly positioned as a standard first-line therapy for managing relapsing forms of MS.